Stuart, FL (January 24, 2024) – Linical, a global Contract Research Organization (CRO) for full-service drug development, has been named the recipient of a recent industry award. The organization has been awarded the title of Best International CRO Service Provider 2023.
Linical’s distinction as a top international CRO service provider is part of the Global Excellence Awards, presented by Global Health & Pharma (GHP) Magazine. The 2023 Global Excellence Awards, now in their fourth year, have been designed to recognize companies, teams, and individuals who are excelling in the ever-growing industry of healthcare. Recipients of the award are deemed innovators in their field, who set the highest standards by pushing boundaries and creating the most cutting-edge medical solutions. Award winners are carefully selected by GHP Magazine’s committee, based on a comprehensive analysis and research process. Adopting this methodology ensures recipients are selected based purely on merit – not popularity – to recognize the leading players in the life science industry.
“The Linical team is proud to be awarded this prestigious industry award for Best International CRO Service Provider 2023 – FL,” stated Isao Sakamoto, Ph.D., CEO of Linical’s Western Region. “We realize biopharma companies have choices when selecting the right CRO partner to support their important clinical research programs. Linical is honored to be recognized as a leading international CRO for full-service drug development by GHP Magazine. This is a testament to our hard-working team and the innovative solutions they provide our clients, spanning the globe’s top pharmaceutical markets such as the Americas, Europe, and Asia-Pacific (APAC).”
The award comes during a time when the clinical development environment is rapidly changing. The industry is seeing an increased demand for global trials and the adoption of technology to support more efficient clinical research.
Dr. Sakamoto added, “Linical is one of a few CROs that comprehensively covers the Americas, Europe, and APAC with our own dedicated staff. We pride ourselves on flexibility while working with all size clients as well as partnering with CROs that need additional coverage in specific regions. We are seeing record volume to start off 2024, which is a good sign for market improvement. This volume of business combined with our loyal clients makes us very excited for the year ahead. We have maintained our commitment to quality which is why we have been asked to participate in so many ‘rescue studies.’ Here at Linical, we believe we have the right size, right reach, and right team to support our clients throughout their entire clinical development journey.”
Linical is a public, mid-sized Contract Research Organization headquartered in Japan with a significant presence across all major markets including North America, Europe, and Asia-Pacific. Linical provides the full spectrum of drug development services from early stage to large-scale, multinational studies. Our areas of focus include Phase I-IV studies in oncology, neurology & psychiatry, immunology & vaccine, and endocrinology & metabolic diseases.
Director, Marketing & Corporate Communications